Baird Financial Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.71M | Sell |
53,394
-4,426
| -8% | -$556K | 0.01% | 625 |
|
|
2025
Q1 | $6.39M | Buy |
57,820
+3,103
| +6% | +$343K | 0.01% | 603 |
|
|
2024
Q4 | $7.47M | Buy |
54,717
+24,657
| +82% | +$3.37M | 0.01% | 574 |
|
|
2024
Q3 | $3.46M | Sell |
30,060
-38,906
| -56% | -$4.48M | 0.01% | 802 |
|
|
2024
Q2 | $9.49M | Buy |
68,966
+36,799
| +114% | +$5.07M | 0.02% | 496 |
|
|
2024
Q1 | $4.44M | Buy |
32,167
+6,582
| +26% | +$908K | 0.01% | 699 |
|
|
2023
Q4 | $3.37M | Sell |
25,585
-837
| -3% | -$110K | 0.01% | 780 |
|
|
2023
Q3 | $2.97M | Buy |
26,422
+178
| +0.7% | +$20K | 0.01% | 788 |
|
|
2023
Q2 | $2.47M | Buy |
26,244
+13,710
| +109% | +$1.29M | 0.01% | 844 |
|
|
2023
Q1 | $1.27M | Sell |
12,534
-4,938
| -28% | -$500K | ﹤0.01% | 1029 |
|
|
2022
Q4 | $2.09M | Buy |
+17,472
| New | +$2.09M | 0.01% | 856 |
|
|
2022
Q1 | – | Sell |
-3,460
| Closed | -$295K | – | 1892 |
|
|
2021
Q4 | $295K | Hold |
3,460
| – | – | ﹤0.01% | 1681 |
|
|
2021
Q3 | $332K | Hold |
3,460
| – | – | ﹤0.01% | 1631 |
|
|
2021
Q2 | $337K | Sell |
3,460
-1,013
| -23% | -$98.7K | ﹤0.01% | 1545 |
|
|
2021
Q1 | $435K | Buy |
+4,473
| New | +$435K | ﹤0.01% | 1392 |
|